State-of-the-art workplace for nuclear medicine and PET radiopharmaceuticals manufacturing.
BIONT, a.s. is a joint stock company focused on the area of nuclear medicine with an emphasis on Positron Emission Tomography (PET). The company’s main goal is to produce and distribute radiopharmaceuticals for logistically available PET centres and provide PET/CT and SPECT/CT imaging for patients from the Slovak Republic and abroad. The company’s main focus is also closely related to research and development in the production of radionuclides, radiopharmaceuticals, and manufacturing equipment, as well as education, training and sharing of the company’s proprietary know-how.
Shortly after its foundation in 2005, BIONT has become one of the most prominent manufacturers of PET radiopharmaceuticals and providers of outpatient care in the area of nuclear medicine. Examinations of patients using the PET/CT and SPECT/CT tomographs started already in the first year of the company’s operation. At the same time, a trial licensed production of Fludeoxyglucose F18 (FDG) was launched and since 2006, BIONT has been supplying FDG to every PET centre in Slovakia with. In 2009, it started its regular supplies of radiopharmaceuticals abroad, as well. The company’s product – biont FDG radiopharmaceutical is currently registered, besides Slovakia, also in another two EU states – in Czechia and Austria. Another company’s product, (18F) Fluorocholine BIONT has been registered in Slovakia since 2020.
BIONT company is aware of its responsibilities regarding the quality of its products and services in radionuclide diagnostics, radionuclides and radiopharmaceuticals manufacturing, and the application of ionic bonds, and is therefore developing and documenting the Quality Management System in order to fulfil the provisions and legal requirements, satisfy the needs of its customers and enhance the company management. The quality system is based on best practices and is subject to the international standard STN EN ISO 9001:2009.
The company’s quality policy monitors the satisfaction rate among diagnosed and treated patients, company’s personnel, as well as other organisations and citizens living in its proximity.
The company culture’s priority is modern diagnostics using radionuclide methods, the result of which brings important and sensitive news for patients and their doctors. The process of diagnosing patients using PET/CT itself is not included in the quality management system certification, but it is counted upon for the future.
Working with short-lived radionuclides in a punctual, just-in-time fashion places high demands on the quality of personnel, provision of reliable technical equipment, and the quality of work environment. The company takes technical measures to reduce the radiation exposure of personnel, patients and the population based on ALARA principles, i.e. as low as possible at reasonable costs, especially by strategically focusing on the automation of production and control procedures.